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Abstract 
Background  
The coronary heart disease (CHD) risk locus on 21q22 (lead SNP rs9982601) lies within a “gene 
desert”. The aim of this study was to assess if this locus is associated with CHD risk factors, and to 
identify the functional variant(s) and gene(s) involved.  
 
Methods  
A phenome scan was performed with UCLEB consortium data. Allele-specific protein binding was 
studied using electrophoretic mobility shift assays. Dual-reporter luciferase assays were used to 
assess the impact of genetic variation on expression. Expression quantitative trait analysis was 
performed with Advanced Study of Aortic Pathology (ASAP) and Genotype-Tissue Expression (GTEx) 
consortium data.  
Results 
A suggestive association between QT interval and the locus was observed (rs9982601p=0.04). One 
variant at the locus, rs28451064, showed allele-specific protein binding and its minor allele showed 
12 % higher luciferase expression (p=4.82x10-3) compared to the common allele. The minor allele of 
rs9982601 was associated with higher expression of the closest upstream genes (SLC5A3 1.30-fold 
increase p=3.98x10-5; MRPS6 1.15-fold increase p=9.60x10-4) in aortic intima media in ASAP. Both 
rs9982601 and rs28451064 showed a suggestive association with MRPS6 expression in relevant 
tissues in the GTEx data.  
 
 Conclusions 
A candidate functional variant, rs28451064, was identified. Future work should focus on identifying 
the pathway(s) involved.  
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Introduction: 
The coronary heart disease (CHD) risk locus on chromosome 21q22 (lead SNP - rs9982601) is typical 
of many variants associated with common disease in genome-wide association studies (GWAS) in 
that the locus falls in an intergenic region and is not associated with any major CHD risk factors (1). 
As such, there is no obvious mechanism through which it is affecting CHD risk. Neither the lead SNP 
at the 21q22 risk locus nor any SNPs in strong  linkage disequilibrium (LD) with it result in changes to 
the protein coding sequence or splice sites in any of the nearby genes. Therefore, the locus does not 
influence CHD risk by altering protein composition or structure. Rather, it is likely that the locus 
elicits its effect through involvement in the regulation of gene expression (2). A feature of the GWAS 
methodology is that a prior hypothesis of which loci are influencing a trait or disease is not required. 
Therefore, it has the potential to identify risk variants and ultimately molecular pathways which 
otherwise would remain obscure. However, to fully take advantage of this, functional analysis of 
GWAS loci is required to determine the mechanism(s) involved.  
The closest downstream gene to the risk locus is the potassium channel subunit encoding KCNE2. 
Mutations in this protein are known to cause long-QT syndrome (3), which is associated with 
arrhythmias and sudden cardiac death. Furthermore, even within the normal range, longer QT-
interval has been associated with increased risk of CHD mortality (4), although  it is unclear whether 
the association is a causal relationship. Upstream of the risk locus, the closest genes are SLC5A3 and 
MRSP6. These genes share an exon which is in the open reading frame for MRPS6 but not SLC5A3 
(5). SLC5A3 (solute carrier family 5-inositol transporter) encodes a sodium myo-inositol transporter 
which is involved in the response to hyperosmotic stress (6). MRPS6 (mitochondrial ribosomal 
protein 6) encodes a subunit of the mitochondrial ribosome (7). The lead SNP at this locus, 
rs9982601, has been found to be associated with expression of MRPS6 in blood, with the risk allele 
showing increased expression (8), indicating that risk locus might be involved in regulating the 
expression of this gene. However, none of these genes point to a plausible pathway to account for 
the association with CHD and thus genomic location does not suggest any obvious mechanism 
through which this CHD risk locus is acting. 
As part of our ongoing functional analysis of GWAS identified CHD risk loci we sought to investigate 
the mechanism through which the 21q22 risk locus influences CHD risk. The aims of this study were 
firstly to assess whether the risk locus was associated with any traits that may give insight into the 
mechanism through which the locus affects risk by performing a phenome scan using data from the 
University College, London School of Hygiene and Tropical Medicine, Edinburgh and Bristol (UCLEB) 
consortium of large-scale cohort studies. Secondly, we sought to identify candidate functional SNP(s) 
using in vitro assays and thirdly to assess relationship between the risk locus and gene expression by 
performing expression quantitative trait loci (eQTL) analysis with data from the Advanced Study of 
Aortic Pathology (ASAP) and the Genotype-Tissue Expression (GTEx) consortium.  
 
 
 
 
Methods: 
 
Phenome scan 
The University College, London School of Hygiene and Tropical Medicine, Edinburgh and Bristol 
(UCLEB) Consortium comprises 12 prospective studies and has been described in detail elsewhere 
(9). Approximately 21,000 participants included in the UCLEB studies were genotyped using the 
Metabochip (10). This platform has approximately 200,000 SNPs, designed to cover regions 
associated with cardio-metabolic disease. Traits available included a number of physiological 
phenotypes, lipid measures and inflammatory markers. Informed consent was obtained for all 
subjects included in UCLEB research. Written approval from individual Research Ethics Committees 
to use anonymised individual level data has been obtained by each participating study. 
Bioinformatics 
Haploreg v2 (11) was used to characterise the lead SNP at the risk locus and those in strong LD with 
it. LD data came from the 1000 Genomes Project phase 1. The annotations displayed include 
chromatin state assignments from the ENCODE project (12) and the Roadmap Epigenomics 
Consortium (13) as well as DNA hypersensitivity site and protein binding annotations from the 
ENCODE project. Predicted changes in transcription factor binding were assessed using the 
Genomatix software suite (Genomatix Software GmbH, Munich, Germany). 
Electrophoretic Mobility Shift Assay (EMSA) 
Hepatocellular carcinoma cell lines (Huh-7 and HepG2) were obtained from the European Collection 
of Cell Cultures. The cells were cultured and nuclear proteins extracted as described in (14). Probes 
with 25 bases flanking the SNP of interest were designed (two per SNP, one for each allele), 
biotinylated and annealed to form double stranded oligonucleotides. Probe sequences are given in 
Supplementary Table 1. The probes were incubated with nuclear extract (with or without 
competitor) at 25oC for 50 minutes. Following this the reactions were run on a 6% polyacrylamide 
gel for 210 minutes at 120 V and thereafter transferred on to Hybond-N+ membrane using Southern 
transfer (15). DNA-protein complexes were cross-linked to the membrane and visualised and using 
the ThermoScientific Lightshift Chemiluminescent Nucleic Acid Detection Module (according to 
the manufacturer’s instructions, Thermo Fisher Scientific - Waltham, MA, USA).  
Dual-Reporter Luciferase Assay 
The region surrounding the putative functional SNP was cloned into the pGL3 promoter vector 
(Promega, Madison, WI, USA) at the enhancer region using the SalI/BamHI restriction sites.  Huh-7 
cells were seeded 1-5x10-4 cells/well and grown to near confluence. The cells were then transfected 
using lipofectamine (Invitrogen, Life Technologies, Carlsbad CA, USA) according to the 
manufacturer’s instructions and left for 48 hours. Reporter plasmid DNA and co-transfectant DNA 
(pRL-TK) were added to each well in a ratio of 200:1. Luciferase activity was determined by 
measuring the luminescence of the cell lysate using the TR717 Microplate Luminometer and the 
Dual Luciferase assay kit (Promega, Madison, WI, USA) according to the manufacturer’s instructions. 
The ratio of firefly luciferase readings : Renilla luciferase readings was then compared between the 
different constructs using paired t-tests. Four runs of eleven or twelve replicates were performed.  
eQTL Analysis  
ASAP: Patients undergoing aortic value surgery at the Karolinksa University Hospital, Stockholm, 
Sweden were recruited (n=213) into ASAP (16). Tissue biopsies were taken from the mammary 
artery, aortic adventitia, aortic intima media heart and liver. Messenger RNA was extracted and 
measured using the Affymetrix Gene Chip Human Exon 1.0 ST expression array (Santa Clara, CA, 
USA). Genotyping was performed using the Illumina Human 610W Quad Beadarrays (San Diego, CA, 
USA). All participants gave informed consent and the study had approval from the ethical committee 
of the Karolinska Institute.  The ASAP data was used to assess the relationship between the risk locus 
and the closest upstream and downstream genes – SLC5A3, MRPS6 and KCNE2 – in the five available 
tissues.   
 
GTEx: The GTEx consortium seeks to provide a resource to study the relationship between genetic 
variation and gene expression by collecting multiple samples from densely genotypes donors (17). 
The data is publically available on the GTEx browser (http://gtexportal.org/home/). The GTEx data 
was used to assess the relationships between SNPs at the risk locus with MRPS6 and KCNE2 
expression in the aortic artery, coronary artery, tibial artery, atrial appendage, left ventricle liver and 
whole blood.  
 
 
 
 
Results:  
Association of the 21q22 CHD risk locus with CHD risk factors 
A phenome scan of the UCLEB consortium data was performed to determine if SNPs at the 21q22 
risk locus were associated with risk factors for CHD. Four SNPs at the 21q22 locus were analysed, the 
lead SNP rs9982601 and three SNPs in moderate LD with it, rs8131284 (r2=0.78), rs7278204 (r2=0.76) 
and rs973754 (r2=0.75). Over one hundred traits were tested (these are listed in the appendix) but 
none met the Bonferroni-adjusted significance threshold (p=4.72x10-4, based on an un-adjusted 
significance threshold of p=0.05). Only one trait, QT interval, showed a suggestive association 
(p<0.05) with the effect in the same direction for all four SNPs (Table 1). The minor CHD risk allele 
was nominally associated with longer QT interval. This putative association is of interest due to the 
close proximity of the potassium ion channel gene KCNE2 to the risk locus. 
Identification of a putative functional SNP  
Bioinformatics analysis of the CHD risk locus 21q22 
Five SNPs in strong LD (r2>0.8) with the lead SNP rs9982601 were identified using Haploreg v2 (11). 
Only one SNP (rs28451064) resided within an enhancer region (in the liver cell line HepG2). This SNP 
was also found to be positioned within a site bound by multiple transcription factors including 
specificity protein 1 (SP1) and forkhead box A2 (FOXA2), also in HepG2 cells.  
Assessment of allele-specific binding  
EMSAs were performed for the lead SNP and the five in strong LD with it, to assess if any of the SNPs 
showed allele-specific binding. The assays were carried out with nuclear extracts from two 
hepatocyte carcinoma cell lines, HepG2 and Huh-7, as the only enhancer chromatin marks found for 
any of the SNPs at this locus were in HepG2 cells. Only rs28451064 showed consistent allele-specific 
binding (Figure 1). Therefore, the result of the EMSAs together with the bioinformatics analysis 
identifies rs28451064 as a strong candidate to be the functional SNP.  
Impact of rs28451064 on transcription factor binding  
To assess whether transcription factor binding may be affected by the presence of different alleles at 
rs28451064, the Genomatix software suite (Genomatix Software GmbH, Munich, Germany) was 
used. Presence of the minor “A” allele rather than the major “G” allele was predicted to abolish a 
vitamin D receptor-retinoid X receptor heterodimer (VDR-RXR) binding site and a homeodomain 
protein H6 family member 3 (HMX3) binding site. The software also predicted the creation of a 
forkhead-related transcription factor 4 (FREAC4) binding site in the presence of the (minor) A allele.  
To investigate whether VDR or RXR, were binding to the rs28451064 probes in vitro, competitor 
EMSAs were performed with both Huh-7 and HepG2 nuclear extracts. SP1 and FOXA2 were also 
investigated as these proteins had been found to bind at this locus in the HepG2 cell line in the 
ENCODE project (Figure 2). SP1 binding to its consensus sequence was not competed out by the 
addition of the rs28451064-G probe and the RXR consensus probe did not bind proteins in either 
extract, demonstrating that these were unlikely to be the bound factor. There were no consistent 
binding results with FOXA2 and VDR, thus no firm conclusions on their binding to rs28451064 in vitro 
could be drawn.  
Impact of rs28451064 on reporter gene expression 
The impact of rs28451064 on gene expression was assessed using a luciferase dual-reporter assay.  
To do this, a fragment of 300 bp containing the SNP was cloned into the enhancer site of the pGL3 
promoter vector and the plasmids transfected into Huh-7 cells. Figure 3 shows the relative 
expression of the reporter gene containing the rs28451064 insert compared to the pGL3 promoter 
plasmid. Both rs28451064 plasmids showed higher expression (A allele 87 % higher p=1.90x10-15, G 
allele 62 % higher p=9.74x10-15) than the pGL3 promoter plasmid, suggesting that this region acts as 
an enhancer. Moreover, in agreement with the eQTL data presented below, the minor A (risk) allele 
was found to have 12 % higher expression compared to the G allele (p=4.82x10-3).  
eQTL Analysis 
The relationship between the lead SNP at the risk locus and expression of its three closest genes 
MRPS6, SLC5A3 and KCNE2 was examined using data from the ASAP study (16). Expression levels in 
five tissues (liver, mammary artery, aortic adventitia, aortic intima media and heart) and rs9982601 
genotype data was available for 106 ASAP participants. The minor CHD risk allele was associated 
with higher expression of the mRNA transcript in aortic intima media for both SLC5A3 and MRPS6 
(SLC5A3 1.30 fold (95% CIs 1.16-1.47) per A allele p=3.98x10-5; MRPS6 1.15 fold (95% CIs 1.06-1.25) 
per A allele p=9.60x10-4 Figure 4). However, no association was observed for KCNE2.  Similar results 
were observed for rs28451064 (SLC5A3 1.40 fold increase per minor allele, p=1.08x10-6; MRPS6 1.20 
fold increase per minor allele, p=1.47x10-5) 
The relationship between the 21q22 CHD risk locus and gene expression was further studied using 
publically available data from the GTEx project (http://www.gtexportal.org/) (17). No genes met the 
significance threshold for a single tissue eQTL with either the lead SNP rs9982601 or the putative 
functional SNP rs28451064. The search was then narrowed to consider the relationship between the 
risk locus and the three genes located most closely to it, KCNE2, MRPS6 and SLC5A3, in seven 
relevant tissues (Table 2). This gives a Bonferroni-adjusted p-value of 4x10-3 (based on an unadjusted 
significance threshold of p=0.05). In agreement with the ASAP results, the minor allele of rs9982601 
was found to be associated with higher expression of MRPS6 in the aortic (effect of minor allele 
relative to common allele=0.15, p=3.5x10-3) and tibial arteries (effect of minor allele relative to 
common allele=0.15, p=1.8x10-4), although not in the coronary artery. There was a suggestive 
association between the minor allele and lower expression of MRPS6 in whole blood (effect of minor 
allele relative to common allele=-0.09, p=0.04).There were suggestive associations between the 
minor allele of rs9982601 and higher expression of KCEN2 in aortic and tibial artery tissue (effect of 
minor allele relative to common allele=0.13, p=0.06 and effect of minor allele relative to common 
allele=0.15, p=0.02, respectively). Expression data for SLC5A3 was not available. Results for 
rs28451064 were very similar (data not shown).  
 
 
 
Discussion 
The locus on chromosome 21q22 has been consistently associated with CHD, with an odds ratio of 
1.13 per minor allele in the CARDIoGRAMplusC4D meta-analysis (1), which is relatively high for a 
GWAS-identified risk variant. However, like the majority of the confirmed GWAS loci for CHD, there 
is no obvious functional mechanism through which the locus influences CHD risk (1). In this study, 
rs28451064 was identified as a putative functional SNP at the locus. The minor CHD risk allele was 
found to show less protein binding and be associated with higher gene expression in vitro. This allele 
was also found to be associated with higher expression of the two closest upstream genes (MRPS6 
and SLC5A3) in a number of tissues. In agreement with previous studies, no significant association 
between the lead SNP, rs9982601, and risk factors for CHD was observed. A suggestive association 
between the risk locus and QT interval was observed, indicating that it may be affecting CHD risk 
through regulating the expression of the potassium channel subunit gene KCNE2, the closest 
downstream gene to the risk locus. However, while a suggestive association between rs9982601 and 
KCNE2 expression in the aortic and tibial arteries was observed in the GTEx data, the evidence for 
the risk locus being involved in the regulation of MRPS6 and SLC5A3 was more consistent. These 
data raise the possibility that the risk locus is acting on more than one pathway influencing the 
development of CHD.  
While a putative functional SNP was identified, the transcription factors involved remain to be 
identified. The minor (risk) allele of rs28451064 was predicted to abolish a binding site for the VDR-
RXR heterodimer transcription factor complex. A large scale analysis performed in lymphoblastoid 
cells found that expression of both MRPS6 and SLC5A3 increased in response to treatment with 
calcitriol (a bioactive form of vitamin D) (18). This suggests that the VDR pathway is involved in 
expression of these two genes, although if so, it is not a simple relationship given that higher 
expression of both genes is associated with the minor (risk) allele which is also predicted to abolish 
the VDR binding site. The competitor EMSAs performed herein investigated which transcription 
factors were binding the rs28451064-G probe, however the results were inconsistent and VDR 
binding to the probe could neither be confirmed nor refuted.   
How increased expression of any of the nearby genes (MRPS6, SLC53 and KCNE2) might affect CHD 
risk is unclear. As a constituent part of the mitochondrial ribosome, the gene product of MRPS6 
plays a key role in the synthesis of the thirteen proteins encoded in mitochondrial DNA, all of which 
are involved in oxidative phosphorylation (19). An important by-product of oxidative 
phosphorylation is the generation of reactive oxygen species (ROS) (20). Overproduction of ROS by 
dysfunctional mitochondria has been associated with multiple pro-atherogeneic consequences 
including the activation of inflammatory pathways and endothelial dysfunction, but whether this is a 
causal relationship remains to be determined (21). If so, it may be that increased expression of 
MRPS6 caused by presence of the risk allele disrupts the translation of the genes encoded by the 
mitochondrial DNA, increasing the risk of mitochondrial dysfunction and ultimately oxidative stress.  
The sequence of SLC5A3 lies completely within that of MRPS6. The protein encoded by SLC5A3 is a 
sodium-myoinositol co-transporter (SLC5A3). This transporter plays an important role in the 
maintenance of cell volume in response to hyperosmotic stress. As osmolarity of the extracellular 
fluid increases, non-selective cation channels are activated causing sodium ions to enter the cell, 
disrupting cellular ion homeostasis. In response, solute carrier family proteins (including SLC5A3) are 
activated causing increased transport of small organic molecules such as myo-inositol, referred to as 
“compatible osmolytes” to replace inorganic ions (22). Recent evidence has suggested that SLC5A3 is 
also involved in the response to hypotonic stress but this is much less well understood (23). Work in 
mouse models has found that SLC5A3 is involved in the development of the peripheral nervous 
system and respiratory gas exchange (24, 25). From current knowledge there is no obvious 
mechanism to link SLC5A3 with the pathogenesis of CHD. However, as there may be a number of 
pathways which contribute to atherosclerosis yet to be elucidated (indicated by the number of 
GWAS hits with unknown mechanisms), the involvement of SLC5A3 cannot be discounted. 
Alternatively, the association between the risk locus and expression of this gene may simply be a 
consequence of its sharing an exon with MRPS6 (5).  
The relationship between KCNE2 and CHD appears to be complex. The ion channel subunit encoded 
by KCNE2 has a long established relationship with QT interval (and thus with the electrical activity of 
the ventricles). How this may relate to CHD risk is yet to be determined. Recently, deletion of the 
gene was found to promote spontaneous atherosclerotic lesions in mice (26). These mice also had 
raised LDL-cholesterol and impaired glucose tolerance, both pro-atherogenic characteristics (27). 
While results from mice are not directly translatable to humans, this does provide preliminary 
evidence of a causal relationship between KCNE2 and CHD. However, only weak evidence for a 
relationship between the 21q22 risk locus and the gene was observed in this study.  
This work has a number of limitations. Functional molecular assays were performed in hepatocyte 
carcinoma cell lines and these may not be the most appropriate cellular model. However, the 
putative functional SNP, rs28451064, was found to lie in a DNAse I hypersensitivity site, transcription 
binding sites and have enhancer chromatin marks in HepG2 (hepatocyte) cells. This indicates that 
the SNP lies in open chromatin in this cell line and thus may be influencing gene expression. 
Furthermore, since the mechanism through which this locus impacts upon risk remains obscure, it is 
not clear which cell type would serve as the most appropriate model. The luciferase assays were 
performed using the pGL3 promoter vector which contains a general SV40 bacterial promoter. It 
would have been preferable to use the promoter of either MRPS6 or SLC5A3. However, the MRPS6 
promoter is not well characterised and attempts to clone the SLC5A3 promoter sequence into the 
pGL3 basic plasmid were unsuccessful. A further limitation is that the in vitro assays performed 
herein are unable to take account of chromatin state or to assess long distance interactions. 
However, chromatin capture techniques are now in mainstream use which can overcome this issue. 
The methods can be used to investigate whether two loci interaction (chromatin conformation 
capture – 3C (28)) or to identify interaction partners for a particular locus circular chromosome 
confirmation capture (29)). Future work on this locus should focus on this.  
In conclusion, functional analysis of the 21q22 CHD risk locus was performed, identifying a putative 
functional SNP, rs28451064. However, the affected gene(s) and transcription factor(s) remain 
obscure. Future work should focus on identifying the pathway(s) through which this locus influences 
CHD risk, specifically the transcription factors and genomic loci involved.   
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Tables:  
Table 1: The association between four SNPs at the CHD risk locus on chromosome 21q22 
and mean QT interval in UCLEB.  
 
Mean QT interval is shown by genotype as well as the beta coefficient (±standard deviation) 
for the minor allele at each SNP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP     Beta-
coefficient 
p-value 
rs9982601 Genotype CC TC TT  
1.83  
(0.90) 
 
0.04 n  
(frequency)  
5329  
(0.75) 
1643 
(0.23) 
130  
(0.02) 
Mean QT 
interval (ms)     
402.8 
(37.35) 
404.5  
(39.28) 
409.1 
(41.08) 
rs8131284 Genotype TT CT CC  
2.14  
(0.89) 
 
0.02 n  
(frequency)  
5293  
(0.75) 
1670 
(0.24) 
142  
(0.02) 
Mean QT 
interval (ms)     
402.7 
(37.41) 
404.9 
(39.20) 
408.1 
(38.97) 
rs7278204 Genotype AA GA GG  
2.07  
(0.89) 
 
0.02 n  
(frequency)  
5290  
(0.74) 
1673 
(0.24) 
141  
(0.02) 
Mean QT 
interval (ms)     
402.7 
(37.73) 
404.9 
(38.19) 
407.9 
(39.26) 
rs973754 Genotype AA GA GG  
1.85  
(0.89) 
 
0.02 n  
(frequency)  
5300  
(0.75) 
1663 
(0.23) 
142  
(0.02) 
Mean QT 
interval (ms)     
402.7 
(37.75) 
404.6 
(38.18) 
408.2 
(38.84) 
 
 
Table 2: Relationship between rs9982601 and expression of selected genes in seven tissues 
from GTEx (http://www.gtexportal.org/home/) 
Effect sizes refer to the effect of the minor allele on expression relative to the common 
allele. se=standard error. 
 
 
 
 
Gene Tissue n Effect Size (se) p-value 
MRPS6 Aortic Artery  197 0.15 (0.05) 3.5x10-3 
MRPS6 Coronary Artery 118 0.14 (0.11) 0.22 
MRPS6 Tibial Artery 285 0.15 (0.05) 1.8x10-3 
MRPS6 Atrial Appendage 159 -0.02 (0.09) 0.88 
MRPS6 Left Ventricle (Heart) 190 -0.16 (0.10) 0.09 
MRPS6 Liver 97 -0.19 (0.14) 0.17 
MRPS6 Whole Blood 338 -0.09 (0.04) 0.04 
KCNE2 Aortic Artery  197 0.13 (0.07) 0.06 
KCNE2 Coronary Artery 118 0.09 (0.11) 0.43 
KCNE2 Tibial Artery 285 0.15 (0.06) 0.02 
KCNE2 Atrial Appendage 159 0.13 (0.16) 0.41 
KCNE2 Left Ventricle (Heart) 190 -0.06 (0.14) 0.71 
KCNE2 Liver 97 0.05 (0.15) 0.31 
KCNE2 Whole Blood 338 8.40x10-3 (0.15) 0.92 
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Figure 1: Replication of EMSAs with A) rs60687299 B) rs977419 C) rs977093 D) rs9982601 and E) rs28451064 probes using HepG2 and Huh-
7 nuclear extract 
 
Binding by both alleles was compared for all five SNPs. Only in E (rs28451064) is there strong binding for one allele but complete absence 
of binding for the other in both cell lines.  
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Figure 2: Competitor EMSA results from assays performed with A) SP1 probes B) VDR probes C) RXR probes and D) FOXA2 probes and HepG2 
and Huh-7 nuclear extracts 
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Figure 3: Relative expression of a vector containing the rs284510654 A allele and 
rs28451064 G allele normalised to the pGL3 promoter expression 
 
Relative expression was compared using paired t-tests. Both plasmids containing the 
sequence surrounding rs28451064 showed higher expression (A allele 87 % higher 
p=1.90x10-15, G allele 62 % higher p=9.74x10-15). The A allele was found to have 12 % higher 
expression compared to the G allele (p=4.82x10-3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Expression of A) SLC5A3 and B) MRPS6 in aortic intima media presented by 
rs9982601 genotype in the ASAP study.  
 
 
 
 
 
 
The minor allele of rs9982601 was associated with higher expression of both SLC5A3 (1.30 
fold (95% CIs 1.16-1.47) per A allele p=3.98x10-5) and MRPS6 (1.15 fold (95% CIs 1.06-1.25) 
per A allele p=9.60x10-4). 
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Supplementary Table 1: Probe sequences for SNPs at the 21q22 CHD risk locus 
The SNP position is underlined. EMSA=electrophoretic mobility shift assay.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP - Allele Sequence 
rs9982601 – C CACAGGGCTGCTCCATGGCCTTGGA 
rs9982601 – C  TCCAAGGCCATGGAGCAGCCCTGTG 
rs9982601 – T  CACAGGGCTGCTTCATGGCCTTGGA 
rs9982601 – T  TCCAAGGCCATGAAGCAGCCCTGTG 
rs28451064 – G  CCAGGCCAAAGTGGACACCAAATAC 
rs28451064 – G  GTATTTGGTGTCCACTTTGGCCTGG 
rs28451064 – A  CCAGGCCAAAGTAGACACCAAATAC 
rs28451064 – A  GTATTTGGTGTCTACTTTGGCCTGG 
rs9980618 – C  AGGGTGTCTGCTCCAGCACACCATG 
rs9980618 – C  CATGGTGTGCTGGAGCAGACACCCT 
rs9980618 – T  AGGGTGTCTGCTTCAGCACACCATG 
rs9980618 – T CATGGTGTGCTGAAGCAGACACCCT 
rs60687299 – T  CACTGTATTGAATACTGGAGGCAAC 
rs60687299 – T  GTTGCCTCCAGTATTCAATACAGTG 
rs60687299 – C CACTGTATTGAACACTGGAGGCAAC 
rs60687299 – C  GTTGCCTCCAGTGTTCAATACAGTG 
rs9977419 – T  TGTGATAGTGAGTGAGTTCTTACGA 
rs9977419 – T  TCGTAAGAACTCACTCACTATCACA 
rs9977419 – A    TGTGATAGTGAGAGAGTTCTTACGA 
rs9977419 – A  TCGTAAGAACTCTCTCACTATCACA 
rs9977093 – G CCATGCAGAACTGTGAATCAATTAA 
rs9977093 – G TTAATTGATTCACAGTTCTGCATGG 
rs9977093 – A CCATGCAGAACTATGAATCAATTAA 
rs9977093 – A TTAATTGATTCATAGTTCTGCATGG 
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The traits included in the phenome scan were – albumin, alcohol use, alkaline phosphate, alanine 
transaminase, apoa1, apob, activated partial thromboplastin time, aspartate aminotransferase, 
basophil count, bilirubin, body mass index, use of blood pressure lowering medication, 
electrocardiogram cornell product, creatinine, C-reactive protein, diastolic blood pressure, D-dimer, 
estimated glomerular filtration rate, eosinophil count, factor VII, factor VIII, ferritin, forced expiatory 
volume in 1 second, fibrinogen, forced vital capacity, gamma-glutamyl transpeptidase, glucose, use 
of glucose lowering drugs, haemoglobin, glyclated haemoglobin, haematocrit, homocysteine, high 
density lipoprotein cholesterol, height, insulin-like growth factor-1, interleukin-6, insulin, low density 
lipoprotein cholesterol, log(alkaline phosphate cholesterol), log(alanine transaminase), log(aspartate 
aminotransferase), log(basophil), log(bilirubin), log(electrocardiogram cornell product), log(C-
reactive protein), log(D-dimer), log(eosinophil count), log(factor VII), log(ferritin),  log(fibrinogen), 
log(gamma-glutamyl transpeptidase), log(glucose), log(homocysteine), log(interleukin-6), 
log(insulin), log(lipoprotein (a)), log(lymphocyte count), log(monocyte count),log(electrocardiogram 
QRS voltage product), log(electrocardiogram QRS voltage sum), log(serum magnesium), log(serum 
phosphate), log(serum urea), log(triglycerides), log(tumor necrosis factor-alpha), log(uric acid), 
log(von Willebrand factor), log(white cell count), lipoprotein (a), lymphocyte count, mean cell 
haemoglobin, mean cell volume, monocyte count, mean platelet volume, neutrophil count, body fat 
percentage, peak expiratory flow, platelet count, PR interval, electrocardiogram QRS voltage 
product, electrocardiogram QRS voltage sum, electrocardiogram QT interval corrected, 
electrocardiogram QT interval, red blood cell count, systolic blood pressure, serum calcium 
concentration, serum magnesium concentration, smoking, electrocardiogram Sokolow Lyon, serum 
phosphate concentration, serum potassium concentration, total serum protein concentration, serum 
sodium concentration, serum urea concentration, total cholesterol, triglycerides, tumour necrosis 
factor-alpha, uric acid, plasma viscosity, von Willebrand factor, white cell count, waist 
circumference, waist-to-hip ratio, weight.  
 
 
 
 
